Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-10-18
2005-10-18
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S573000, C514S913000
Reexamination Certificate
active
06956057
ABSTRACT:
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound which is a EP4agonist.
REFERENCES:
patent: 4994274 (1991-02-01), Chan et al.
patent: 5028624 (1991-07-01), Gluchowski et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 5627208 (1997-05-01), Stjernschantz et al.
patent: 5892099 (1999-04-01), Maruyama et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: 6410591 (2002-06-01), Burk et al.
patent: 0292870 (1988-11-01), None
patent: 0737676 (1996-10-01), None
patent: 0 855 389 (1998-07-01), None
patent: 0860430 (1998-08-01), None
patent: 0 985 663 (2000-03-01), None
patent: 09286775 (1998-02-01), None
patent: 10-265454 (1998-10-01), None
patent: 2000-1472 (2000-01-01), None
patent: 0038663 (2000-07-01), None
patent: 0038667 (2000-07-01), None
Bito, L.Z.,Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252.
Bito, L.Z.,Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S.M. and Neufeld, A.H. eds, New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson et al, Invest.Ophthalmol. Vis. Sci.(suppl), 284 (1987).
Bito, L.Z.,Arch. Ophthalmol.105, 1036 (1987).
Siebold et al,Prodrug5 3 1989.
Matsumura et al, “Prostaglandins having multi-substituted aryloxy groups and their use”, Derwent Publications Ltd., (Sep. 29, 1998).
Dijkstra et al, Repertorium 96/97, p. 1089-1091.
Hirano et al, “Prostaglandin derivative”, Derwent Publications Ltd., (Jun. 5, 2001).
Maruyama et al, “Design and synthesis of a highly selective EP4-receptor agonist”, Bioorganic & Medicinal Chemistry Letters (2001), 2029-2031.
Burk Robert M.
Holoboski Mark
Krauss Achim H.
Posner Mari F.
Woodward David F.
Allergan Inc.
Baran Robert J.
Donovan Stephen
Fay Zohreh
Voet Martin A.
LandOfFree
EP4 agonists as agents for lowering intraocular pressure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP4 agonists as agents for lowering intraocular pressure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP4 agonists as agents for lowering intraocular pressure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457697